$NBIX
NEUROCRINE BIOSCIENCES INC

2023 Q2 Form 10-Q Financial Statement

#000091447523000044 Filed on May 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $452.7M $420.4M
YoY Change 19.7% 35.35%
Cost Of Revenue $11.50M $8.500M
YoY Change 139.58% 84.78%
Gross Profit $441.2M $411.9M
YoY Change 18.16% 34.61%
Gross Profit Margin 97.46% 97.98%
Selling, General & Admin $221.8M $242.7M
YoY Change 21.33% 20.93%
% of Gross Profit 50.27% 58.92%
Research & Development $145.8M $139.5M
YoY Change 7.28% 36.5%
% of Gross Profit 33.05% 33.87%
Depreciation & Amortization $5.100M $4.100M
YoY Change 30.77% 24.24%
% of Gross Profit 1.16% 1.0%
Operating Expenses $367.6M $382.2M
YoY Change 15.34% 26.18%
Operating Profit $73.60M -$114.2M
YoY Change 34.55% -3783.87%
Interest Expense $48.00M $1.100M
YoY Change 2081.82% -57.69%
% of Operating Profit 65.22%
Other Income/Expense, Net $48.00M $10.90M
YoY Change -161.54% -40.44%
Pretax Income $121.6M -$103.3M
YoY Change -621.89% -582.71%
Income Tax $26.10M -$26.70M
% Of Pretax Income 21.46%
Net Earnings $95.50M -$76.60M
YoY Change -665.09% -651.08%
Net Earnings / Revenue 21.1% -18.22%
Basic Earnings Per Share $0.98 -$0.79
Diluted Earnings Per Share $0.95 -$0.79
COMMON SHARES
Basic Shares Outstanding 97.57M shares 96.59M shares
Diluted Shares Outstanding 100.2M shares 97.10M shares

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $976.7M $894.6M
YoY Change 50.66% 34.55%
Cash & Equivalents $160.2M $103.8M
Short-Term Investments $816.5M $790.8M
Other Short-Term Assets $100.6M $113.2M
YoY Change 60.45% 86.18%
Inventory $31.70M $33.40M
Prepaid Expenses
Receivables $387.6M $391.6M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.497B $1.433B
YoY Change 46.83% 40.72%
LONG-TERM ASSETS
Property, Plant & Equipment $149.1M $62.80M
YoY Change 123.2% -1.72%
Goodwill $5.700M $5.600M
YoY Change
Intangibles $36.90M $37.20M
YoY Change
Long-Term Investments $515.6M $380.3M
YoY Change 5.44% -39.85%
Other Assets $414.9M $24.90M
YoY Change 4049.0% 146.53%
Total Long-Term Assets $1.117B $927.0M
YoY Change 13.19% -17.7%
TOTAL ASSETS
Total Short-Term Assets $1.497B $1.433B
Total Long-Term Assets $1.117B $927.0M
Total Assets $2.613B $2.360B
YoY Change 30.28% 10.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $391.6M $355.7M
YoY Change 47.38% 50.78%
Accrued Expenses $17.70M $17.60M
YoY Change 3.51% 4.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $169.7M $0.00
YoY Change
Total Short-Term Liabilities $582.5M $374.1M
YoY Change 103.89% 47.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $169.5M
YoY Change -100.0% -55.12%
Other Long-Term Liabilities $177.6M $41.30M
YoY Change 534.29% 109.64%
Total Long-Term Liabilities $177.6M $41.30M
YoY Change 534.29% 109.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $582.5M $374.1M
Total Long-Term Liabilities $177.6M $41.30M
Total Liabilities $760.1M $675.3M
YoY Change 30.53% -10.37%
SHAREHOLDERS EQUITY
Retained Earnings -$387.9M -$483.4M
YoY Change -31.26% -11.69%
Common Stock $2.242B $2.171B
YoY Change 12.11% 11.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.853B $1.685B
YoY Change
Total Liabilities & Shareholders Equity $2.613B $2.360B
YoY Change 30.28% 10.04%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income $95.50M -$76.60M
YoY Change -665.09% -651.08%
Depreciation, Depletion And Amortization $5.100M $4.100M
YoY Change 30.77% 24.24%
Cash From Operating Activities $179.6M -$125.2M
YoY Change 30.05% 209.14%
INVESTING ACTIVITIES
Capital Expenditures $6.800M $8.500M
YoY Change -177.27% 11.84%
Acquisitions
YoY Change
Other Investing Activities -$119.1M -$33.60M
YoY Change -396.27% 40.0%
Cash From Investing Activities -$125.9M -$42.10M
YoY Change -500.96% 33.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.900M $8.200M
YoY Change -101.05% 34.43%
NET CHANGE
Cash From Operating Activities 179.6M -$125.2M
Cash From Investing Activities -125.9M -$42.10M
Cash From Financing Activities 2.900M $8.200M
Net Change In Cash 56.60M -$159.1M
YoY Change -152.95% 141.06%
FREE CASH FLOW
Cash From Operating Activities $179.6M -$125.2M
Capital Expenditures $6.800M $8.500M
Free Cash Flow $172.8M -$133.7M
YoY Change 17.63% 177.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000914475
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2022Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P13Y7M
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
0-22705
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
NEUROCRINE BIOSCIENCES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
12780 El Camino Real
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0525145
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92130
CY2023Q1 dei City Area Code
CityAreaCode
(858)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
617-7600
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
NBIX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
97574838 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103800000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
262900000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
790800000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
726400000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
391600000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
350000000.0 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
33400000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
35100000 usd
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
113200000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
79100000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
1432800000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
1453500000 usd
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
337400000 usd
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
305900000 usd
CY2023Q1 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
244600000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
299400000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84400000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
87000000.0 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
135700000 usd
CY2022Q4 us-gaap Equity Securities Fv Ni Current And Noncurrent
EquitySecuritiesFvNiCurrentAndNoncurrent
102100000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
62800000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58600000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37200000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37200000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
24900000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
25000000.0 usd
CY2023Q1 us-gaap Assets
Assets
2359800000 usd
CY2022Q4 us-gaap Assets
Assets
2368700000 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
355700000 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
347600000 usd
CY2023Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
169400000 usd
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
18400000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
20700000 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
374100000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
537700000 usd
CY2023Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
169500000 usd
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
0 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90400000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
93500000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
41300000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29700000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
675300000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
660900000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
220000000 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
97500000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
97500000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
96500000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
96500000 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
100000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2170500000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2122400000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2700000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-7900000 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-483400000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-406800000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1684500000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1707800000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2359800000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2368700000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
420400000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
310600000 usd
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
8500000 usd
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4600000 usd
CY2023Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
139500000 usd
CY2022Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
102200000 usd
CY2023Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
143900000 usd
CY2022Q1 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
242700000 usd
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
200700000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
534600000 usd
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
307500000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-114200000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
3100000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1100000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
2600000 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
2200000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
19900000 usd
CY2023Q1 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
9800000 usd
CY2022Q1 nbix Investment Income And Other Net
InvestmentIncomeAndOtherNet
1000000.0 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
10900000 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
18300000 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103300000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
21400000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-26700000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
7500000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-76600000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
-1200000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
0 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
4000000.0 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-7600000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-71400000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
6300000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97100000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95300000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97100000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97600000 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1707800000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-76600000 usd
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
5200000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
39900000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8200000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1684500000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1374000000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-7600000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
37000000.0 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6100000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1391100000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-76600000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
13900000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
39900000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
37000000.0 usd
CY2023Q1 us-gaap Depreciation
Depreciation
4100000 usd
CY2022Q1 us-gaap Depreciation
Depreciation
3300000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
200000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
400000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
900000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 usd
CY2023Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
2200000 usd
CY2022Q1 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
19900000 usd
CY2023Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-31600000 usd
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-300000 usd
CY2023Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-2400000 usd
CY2022Q1 us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
800000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
41700000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
78000000.0 usd
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1800000 usd
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1500000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6700000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11500000 usd
CY2023Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
24300000 usd
CY2022Q1 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
10700000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-125200000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40500000 usd
CY2023Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
206200000 usd
CY2022Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
192800000 usd
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
203900000 usd
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
176500000 usd
CY2023Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
31300000 usd
CY2022Q1 us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
7700000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8500000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7600000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-42100000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-31600000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8200000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
6100000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8200000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6100000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-159100000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-66000000.0 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
270700000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
344000000.0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111600000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
278000000.0 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
600000 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2800000 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
200000 usd
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
798000000.0 usd
CY2023Q1 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
100000 usd
CY2023Q1 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
7300000 usd
CY2023Q1 nbix Debt Securities Available For Sale Fair Value Current
DebtSecuritiesAvailableForSaleFairValueCurrent
790800000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
735800000 usd
CY2022Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
0 usd
CY2022Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
9400000 usd
CY2022Q4 nbix Debt Securities Available For Sale Fair Value Current
DebtSecuritiesAvailableForSaleFairValueCurrent
726400000 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
246800000 usd
CY2023Q1 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
600000 usd
CY2023Q1 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
2800000 usd
CY2023Q1 nbix Debt Securities Available For Sale Fair Value Noncurrent
DebtSecuritiesAvailableForSaleFairValueNoncurrent
244600000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Noncurrent
DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
304500000 usd
CY2022Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
200000 usd
CY2022Q4 nbix Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Noncurrent
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
5300000 usd
CY2022Q4 nbix Debt Securities Available For Sale Fair Value Noncurrent
DebtSecuritiesAvailableForSaleFairValueNoncurrent
299400000 usd
CY2023Q1 nbix Debt Securities Available For Sale Position Number Of Positions
DebtSecuritiesAvailableForSalePositionNumberOfPositions
251 security
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
177 security
CY2023Q1 us-gaap Interest Receivable Current
InterestReceivableCurrent
4400000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
4700000 usd
CY2022Q1 us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 usd
CY2023Q1 us-gaap Debt Securities Available For Sale Accrued Interest Writeoff
DebtSecuritiesAvailableForSaleAccruedInterestWriteoff
0 usd
CY2023Q1 us-gaap Investments
Investments
1282700000 usd
CY2022Q4 us-gaap Investments
Investments
1398600000 usd
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6700000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12000000.0 usd
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
8700000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
5600000 usd
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
18000000.0 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
17500000 usd
CY2023Q1 us-gaap Inventory Net
InventoryNet
33400000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
35100000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
5400000 usd
CY2023Q1 us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
200000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
5600000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
37200000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2600000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3400000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3400000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3400000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3400000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
16700000 usd
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103800000 usd
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
270200000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7800000 usd
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7800000 usd
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
111600000 usd
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
278000000.0 usd
CY2022Q1 nbix Lessee Operating Lease Option Term To Construct Fifth Building
LesseeOperatingLeaseOptionTermToConstructFifthBuilding
P6Y
CY2022Q1 nbix Rent Abatement Period
RentAbatementPeriod
P10M
CY2022Q1 nbix Lessee Operating Lease Monthly Base Rent Per Square Foot
LesseeOperatingLeaseMonthlyBaseRentPerSquareFoot
6 usd
CY2022Q1 nbix Annual Rent Escalation Percentage
AnnualRentEscalationPercentage
0.03
CY2022Q1 nbix Number Of Renewal Options
NumberOfRenewalOptions
2 renewaloption
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7800000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4100000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
4100000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4400000 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
4000000.0 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y8M12D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.053
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.052
CY2023Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Four
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFour
41900000 usd
CY2023Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Five
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearFive
479700000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
13500000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
17400000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
15900000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
15700000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16000000.0 usd
CY2023Q1 nbix Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
54400000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
132900000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24900000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
108000000.0 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
17600000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
90400000 usd
CY2023Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Two
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearTwo
17200000 usd
CY2023Q1 nbix Non Cancelable Future Minimum Lease Payments For Operating Leases Not Yet Commenced Year Three
NonCancelableFutureMinimumLeasePaymentsForOperatingLeasesNotYetCommencedYearThree
33300000 usd
CY2023Q1 nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
900000 usd
CY2022Q1 nbix Debt Instrument Coupon Interest
DebtInstrumentCouponInterest
2200000 usd
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
200000 usd
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
1100000 usd
CY2022Q1 us-gaap Interest Expense
InterestExpense
2600000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-76600000 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-76600000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13900000 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
13900000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
97100000 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
95300000 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97100000 shares
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
97600000 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.79
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.79
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15500000 shares
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6000000.0 shares

Files In Submission

Name View Source Status
0000914475-23-000044-index-headers.html Edgar Link pending
0000914475-23-000044-index.html Edgar Link pending
0000914475-23-000044.txt Edgar Link pending
0000914475-23-000044-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nbix-20230331.htm Edgar Link pending
nbix-20230331.xsd Edgar Link pending
nbix-20230331_g1.jpg Edgar Link pending
q1-2023x10qxexhibit101.htm Edgar Link pending
q1-2023x10qxexhibit101001.jpg Edgar Link pending
q1-2023x10qxexhibit101002.jpg Edgar Link pending
q1-2023x10qxexhibit101003.jpg Edgar Link pending
q1-2023x10qxexhibit101004.jpg Edgar Link pending
q1-2023x10qxexhibit101005.jpg Edgar Link pending
q1-2023x10qxexhibit102.htm Edgar Link pending
q1-2023x10qxexhibit102001.jpg Edgar Link pending
q1-2023x10qxexhibit102002.jpg Edgar Link pending
q1-2023x10qxexhibit102003.jpg Edgar Link pending
q1-2023x10qxexhibit102004.jpg Edgar Link pending
q1-2023x10qxexhibit102005.jpg Edgar Link pending
q1-2023x10qxexhibit102006.jpg Edgar Link pending
q1-2023x10qxexhibit102007.jpg Edgar Link pending
q1-2023x10qxexhibit102008.jpg Edgar Link pending
q1-2023x10qxexhibit102009.jpg Edgar Link pending
q1-2023x10qxexhibit102010.jpg Edgar Link pending
q1-2023x10qxexhibit102011.jpg Edgar Link pending
q1-2023x10qxexhibit102012.jpg Edgar Link pending
q1-2023x10qxexhibit102013.jpg Edgar Link pending
q1-2023x10qxexhibit102014.jpg Edgar Link pending
q1-2023x10qxexhibit102015.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nbix-20230331_cal.xml Edgar Link unprocessable
nbix-20230331_def.xml Edgar Link unprocessable
nbix-20230331_lab.xml Edgar Link unprocessable
nbix-20230331_pre.xml Edgar Link unprocessable
nbix-20230331_htm.xml Edgar Link completed
q1-2023x10qxexhibit102016.jpg Edgar Link pending
q1-2023x10qxexhibit102017.jpg Edgar Link pending
q1-2023x10qxexhibit102018.jpg Edgar Link pending
q1-2023x10qxexhibit102019.jpg Edgar Link pending
q1-2023x10qxexhibit102020.jpg Edgar Link pending
q1-2023x10qxexhibit102021.jpg Edgar Link pending
q1-2023x10qxexhibit102022.jpg Edgar Link pending
q1-2023x10qxexhibit102023.jpg Edgar Link pending
q1-2023x10qxexhibit102024.jpg Edgar Link pending
q1-2023x10qxexhibit103.htm Edgar Link pending
q1-2023x10qxexhibit103001.jpg Edgar Link pending
q1-2023x10qxexhibit103002.jpg Edgar Link pending
q1-2023x10qxexhibit103003.jpg Edgar Link pending
q1-2023x10qxexhibit103004.jpg Edgar Link pending
q1-2023x10qxexhibit103005.jpg Edgar Link pending
q1-2023x10qxexhibit103006.jpg Edgar Link pending
q1-2023x10qxexhibit103007.jpg Edgar Link pending
q1-2023x10qxexhibit103008.jpg Edgar Link pending
q1-2023x10qxexhibit103009.jpg Edgar Link pending
q1-2023x10qxexhibit104.htm Edgar Link pending
q1-2023x10qxexhibit104001.jpg Edgar Link pending
q1-2023x10qxexhibit104002.jpg Edgar Link pending
q1-2023x10qxexhibit104003.jpg Edgar Link pending
q1-2023x10qxexhibit104004.jpg Edgar Link pending
q1-2023x10qxexhibit104005.jpg Edgar Link pending
q1-2023x10qxexhibit104006.jpg Edgar Link pending
q1-2023xexhibit311.htm Edgar Link pending
q1-2023xexhibit312.htm Edgar Link pending
q1-2023xexhibit32.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending